Apoptotic osteocytes and the control of targeted bone resorption by Plotkin, Lilian I.
Apoptotic osteocytes and the control of targeted bone
resorption
Lilian I. Plotkin, PhD
Department of Anatomy & Cell Biology, Indiana University School of Medicine, Indianapolis, IN
46202
Abstract
Studies from the 1950s and 1960s already recognize the fact that osteocytes, although long living
cells, die, as evidenced by accumulation of osteocytic lacunae devoid of cells. More recently, it
was demonstrated that these cells die by apoptosis. The rate of osteocyte apoptosis is regulated by
the age of the bone, as well as by systemic hormones, local growth factors, cytokines,
pharmacological agents, and mechanical forces. Apoptotic osteocytes, in turn, recruit osteoclasts
to initiate targeted bone resorption. This results in the removal of “dead” bone and may improve
the mechanical properties of the skeleton. However, the molecular regulators of osteocyte survival
and targeted bone remodeling are not completely known. In this review, the current knowledge on
the molecular mechanism that lead to osteocyte death or survival, and the signals that mediate
targeted bone resorption is discussed.
Introduction: osteocytes, long living cells that can undergo premature
death
Osteocytes were considered to be inactive bone residents for long time. They are now
believed to be the master regulators of bone remodeling, via the production of soluble
factors that reach the bone marrow and influence the differentiation and behavior of
osteoblasts and osteoclasts [1]. Part of this regulatory mechanism is exerted following
osteocyte death. In particular, osteocyte apoptosis is associated with local bone resorption in
several conditions. This could be due either to the absence of restraining signals or the
release of pro-osteoclastogenic signals by dying osteocytes or their neighbors. In the 1950s
it was shown that radiation damage was associated with osteocyte death, and that osteocytes
located near fractures also died [2]. Later, Harold Frost reported increased osteocyte death
with aging, evidenced by accumulation of empty lacunae [3]; and Dunstan and colleagues
showed increased osteocyte apoptosis in patients with fractures of the femoral neck and
osteoarthritis [2]. The accumulation of dead osteocytes in older individuals was reproduced
more recently in mice, by measuring the prevalence of apoptotic TUNEL positive osteocytes
[4]. In addition, increased osteocyte apoptosis was found in the absence of sex steroids [5,6],
with glucocorticoid excess [7], due to immobilization [8,9], or induced by fatigue loading
[10]. Conversely, agents that preserve bone mass and strength reduce the prevalence of
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osteocyte apoptosis. This is the case for intermittent parathyroid hormone (PTH)
administration [11], bisphosphonates [12], and sex steroids [6,13]. In this review, the current
knowledge on the molecular mechanism that lead to osteocyte death and the signals that
mediate targeted bone resorption will be discussed.
Why osteocytes die?
Parfitt and colleagues have estimated that approximately 2.5% osteocytes die each year, and
that the lifespan of osteocytes can vary from 1 to 50 years [14]. The cause of this
spontaneous apoptosis remains unknown. It is believed that apoptosis is the default fate for
all nucleated cells and only cells that have active survival signals remain alive [15]. For
example, inhibition of osteocyte apoptosis by deletion of the pro-apoptotic proteins Bak and
Bax generates dysfunctional osteocytes [16]. This evidence suggests that a normal rate of
osteocyte death is required to maintain bone health; and, that artificial prolongation of the
life span of osteocytes results in accumulation of cell damage as the age of the bone
increases.
Aging accelerates osteocyte death, by a mechanism associated with increased oxidative
stress, as evidenced by a reduction in anti-oxidant enzymes, and phosphorylation of the
markers of oxidative stress p53 and of p66Shc in bone from aging mice [4]. A similar
mechanism has been proposed for the accumulation of apoptotic osteocytes induced by
removal of sex steroids [5]. Thus, administration of the anti-oxidant N-acetyl Cysteine
prevents the accumulation of reactive oxygen species, the decrease activity of anti-oxidant
enzymes, the increase in phosphorylated p53 and p66shc, and, ultimately, osteocyte
apoptosis in ovariectomized and orchidectomized mice [4].
Accumulation of apoptotic osteocytes is also a feature of glucocorticoid-induced bone
disease in mice and humans [7,12]. In particular, glucocorticoid-induced osteonecrosis and
the consequent collapse of the femoral head are associated with apoptotic osteocytes
localized adjacent to the sub-chondral region [17]. The pro-apoptotic effect of the steroids is
mediated via the glucocorticoid receptor, is independent of gene transcription and results
from the activation of the focal adhesion related kinase Pyk2/JNK signaling pathway [18].
This leads to cell detachment-induced apoptosis (also known as anoikis). Actions of
glucocorticoid on osteoblasts might also contribute to the induction of osteocyte apoptosis.
This includes the local suppression of the synthesis of survival factors such as IGF-1, IL-6,
MMPs [19], and the induction of the Wnt antagonist SFRP-1 [20]. The effect of
glucocorticoids has also been associated with increased oxidative stress [21,22]; and
elevated glucocorticoid levels can contribute to the increase in reactive oxygen species and
osteocyte apoptosis during aging. This was demonstrated by a decrease in osteocyte
apoptosis in 21-month-old mice in which the osteoblasts and osteocytes expressed an
enzyme to locally inactivate glucocorticoids [23].
Mechanical forces also affect osteocyte viability. Lack of mechanical stimulation [8,9] and
excessive loading [10,24] both increase the prevalence of osteocyte apoptosis in mice and
rats. The lack of mechanical forces could decrease survival signals induced by normal
physical activity. In particular, disuse increases the expression of the Wnt inhibitor
sclerostin [25]. By interfering with the survival effect of Wnt signaling activation in
osteocytes, sclerostin also contributes to increasing osteocyte death in the absence of loading
[26]. In osteocytes in the vicinity of microdamage, elevated osteocyte apoptosis is associated
with increased expression of the pro-apoptotic protein Bax, and, coincides with increased
TUNEL staining. Conversely, the anti-apoptotic protein Bcl-2 increases farther away from
the damage focus [27], suggesting the activation of protective signals that avoid widespread
cell death.
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How osteocytes are maintained alive?
Most therapeutic interventions that increase or maintain bone mass and strength also
preserve osteocyte viability. This was first demonstrated following daily injections of PTH,
the only FDA-approved bone anabolic treatment [11]. Although the mechanism by which
PTH prevents osteocyte apoptosis has not been investigated, we have shown using
osteoblastic cells that the hormone prevents glucocorticoid- and etoposide-induced cell
death via activating the PKA/cAMP/CREB signaling pathway [28]. PTH-induced cell
survival also requires the inactivation of the pro-apoptotic protein BAD and increased
synthesis of the anti-apoptotic protein Bcl-2. Interestingly, the transcription factor Runx2 is
required for the survival effect of PTH, but the hormone also induces Runx2 proteosomal
degradation, which limits the duration of the survival effect of PTH. The anti-apoptotic
effect of PTH also requires the expression of connexin43 (Cx43), which sequesters β-
arrestin thereby allowing PTH-induced cAMP production and cell survival [29].
Bisphosphonates are anti-resorptive agents that block osteoclast activity by inhibiting
enzymes of the mevalonate pathway [30]. We showed that bisphosphonates also prevent
osteocyte apoptosis in vitro and in vivo [12]. The drugs exert this effect by opening Cx43
hemichannels, leading to activation of the Src/MEK/ERK pathway [12,31]. The requirement
of Cx43 expression in osteocytes for the anti-apoptotic effect of bisphosphonates, and the
induction of ERK activation in bone, has been demonstrated in vivo [32,33]. Interestingly,
unlike most agents that induce ERK activation, bisphosphonates do not induce the nuclear
translocation of the kinase [34]. Instead, they promote the phosphorylation of the
cytoplasmic target of ERKs p90RSK, followed by phosphorylation of CEBPβ and BAD,
without requiring new gene transcription. The survival effect of bisphosphonates on
osteocytes (and osteoblasts) is distinct from the effect of the drugs on osteoclasts. Thus, it is
exerted at much lower concentrations than the ones required for inhibiting osteoclast
function, it is mediated by activation of the extracellular signal-activated kinases (ERKs),
independently of the mevalonate pathway, and it is reproduced by IG9402, a bisphosphonate
analog that does not affect osteoclasts [33,35].
Both estrogens and androgens prevent osteocyte apoptosis [36,37]. Similar effect has been
demonstrated with the selective estrogen receptor modulator (SERM) LY 117018 [38], but
not with raloxifene [39,40]. The survival effect of the sex steroids can be exerted via
activation of either estrogen or androgen receptor [6], is independent of gene transcription
mediated by the receptors, and can be mimicked by estren, a non-genomic activator of
estrogen receptor [6,37]. Like bisphosphonates, the survival effect of sex steroids depends
on ERK activation, but, unlike bisphosphonates, nuclear accumulation of the kinase and
ERK-activated transcription factors are required [34,39]. The survival effect of sex steroids
also requires the activation of PI3K and JNK, inactivation of the pro-apoptotic protein BAD
and the transcriptional activity of AP-1 [39].
Physiological levels of mechanical stimulation reduce osteocyte apoptosis in rats [24]. We
showed in vitro that mechanical stimulation by biaxial stretching prevents osteocyte
apoptosis by inducing the engagement of integrins and activation of the focal adhesion
kinase FAK [41]. This is followed by Src/MEK/ERK activation, nuclear ERK accumulation
and ERK-mediated gene transcription. In addition, the estrogen receptors ERα and ERβ (but
not the androgen receptor), and their presence in the cell membrane within caveolae, are
required for the survival effect of mechanical loading, albeit in a ligand-independent manner
[42]. Others have shown that membrane shear stress induced by fluid flow in vitro leads to
the opening of Cx43 hemichannels, the release of prostaglandin E2, and osteocytic cell
survival [43]. In this context, prostaglandin E2 induces the activation of both cAMP/PKA
and PI3K/Akt/βcatenin signaling pathways to preserve osteocyte viability.
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Osteocyte apoptosis and osteoclast recruitment: lack of signals from
absent osteocytes versus signals from dying cells
The connection between disruption of the osteocyte network and bone remodeling was first
proposed by Frost (reviewed in [44]). Later, Noble and colleagues observed signs of
apoptosis in osteocytes located in bones with high rates of remodeling in human bone
samples [45]. This led the authors to speculate the existence of a link between osteocyte
apoptosis and bone replacement. This hypothesis is supported by microscopy studies
showing apoptotic osteocytes engulfed by osteoclasts [46–48]. More recently, Schaffler’s
group showed that apoptotic osteocytes in rats subjected to fatigue loading accumulate in
areas where bone resorption occurs [10]. Our group also demonstrated co-localization of
apoptotic osteocytes and osteoclasts in a murine model of reduced mechanical stimulation
[8]. Accumulation of apoptotic osteocytes preceded the increase in osteoclasts, suggesting a
cause-effect relationship between dead osteocytes and bone resorption [8,10]. This
relationship was confirmed in studies in which osteocyte apoptosis was directly blocked
using caspase inhibitors, resulting in a substantial decrease in bone resorption following
fatigue loading and ovariectomy [49,50].
Genetically modified mouse models also help to support the hypothesis that accumulation of
apoptotic osteocytes induces the recruitment of osteoclasts to initiate bone resorption. Using
transgenic mice, expressing the diphtheria toxin receptor in osteocytes, Tatsumi et al showed
that administration of diphtheria toxin not only induces a dramatic increase in apoptotic
osteocytes and empty lacunae, but also accumulation of osteoclasts and cortical bone
porosity [51].
We showed accumulation of apoptotic osteocytes in cortical bone from mice lacking Cx43
in osteoblasts and osteocytes, or in osteocytes only (Figure 1) [52]. This was later confirmed
by Lloyd et al. in mice lacking Cx43 in osteoblasts and osteocytes [53]. In bones from mice
lacking osteocytic Cx43, anatomical mapping of cells showed that apoptotic osteocytes are
preferentially located near endocortical surfaces where osteoclasts accumulate [52].
Interestingly, although deletion of Cx43 results in accumulation of empty lacunae, these did
not localize in any particular region of the cortical bone. This suggests that signals from
dying osteocytes, rather than absence of signals released by living cells, are required to
recruit osteoclasts. However, although some candidate molecules have been proposed [54],
the molecular nature of these signals is not known.
Evidence for some candidate molecules linking osteoclastogenesis to osteocyte apoptosis are
now emerging. For example, viable osteocytes in the vicinity of apoptotic cells express high
RANKL/OPG ratio and elevated VEGF expression in bones subjected to fatigue loading
[55]. Monocyte chemoattractant protein-1 (CCL2) is also specifically regulated at this site
[56], contributing to the localized elevation of osteoclastogenesis. An increase in the
RANKL/OPG ratio is also observed in Cx43 deficient osteocytes [52,57], suggesting that
disruption of cell-to-cell communication between the dying osteocyte and the neighbor
osteocyte might cause the elevation of the pro-osteoclastogenic cytokines in the latter cell.
Still, the signals driving from dying cells to neighboring osteocytes or to the bone marrow
have not been identified. In MLO-Y4 osteocytic cells and primary osteocytes, the apoptotic
osteocyte bodies released by dying cells induce bone resorption in quiescent surfaces of
calvariae [58]. Further, they also stimulate osteoclast differentiation in co-cultures with bone
marrow cells, even in the absence of RANKL. Another candidate to mediate the recruitment
of osteoclasts is the high mobility group box protein 1 (HMGB1), which is released by
apoptotic MLO-Y4 osteocytic cells [59]. HMGB1 is a pro-inflammatory cytokine that can
activate the receptor for advanced glycation end products (RAGE) and the Toll-like receptor
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[60]. HMGB1 induces osteoclastogenesis by activating RAGE [61]. In addition, HMGB1 is
chemotactic for osteoclasts [62], increases RANKL/OPG mRNA ratio, and decreases OPG
release to the cell culture media [59]. Further studies are required to identify the molecules
responsible for the association of apoptotic osteocytes and osteoclast recruitment in targeted
bone resorption in vivo.
Conclusion
Studies from the past 2 decades have underscored the relevance of osteocyte viability for the
maintenance of bone structure and strength. Targeted osteoclast recruitment and localized
bone resorption results in the removal of the “dead” bone, allowing for renewal of the
skeleton and maintenance of bone strength. Conversely, both increased osteocyte apoptosis
and its inhibition throughout life result in defective bone, with increased porosity, altered
bone geometry and deficient mechanical properties. Although advances have been made in
understanding the relationship between osteocyte death and the recruitment of osteoclasts,
the main effectors of this association remain unknown. Complete understanding of the
relationship between osteocyte apoptosis and bone remodelling may lead to the development
of improved therapies to maintain bone health.
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Figure 1.
Transmission electron microscopy images of femoral bone showing a Cx43-expressing
osteocyte from control Cx43fl/− mice (top panel), and a Cx43-deficient osteocyte from mice
lacking Cx43 in osteoblasts and osteocytes (Cx43 ΔOb−Ot/−) (bottom panel). Whereas the cell
on the top contains a nucleus with normal appearance, the one on the bottom exhibit typical
features of a cell undergoing apoptosis, including nuclear condensation and detachment
from the extracellular matrix. Bar indicates 2 μm. Images were taken at the Electron
Microscopy Center of the Department of Anatomy and Cell Biology (Indiana University
School of Medicine). Digital images were taken with an Advanced Microscope Techniques
(Danvers, MA, USA) CCD camera. See [52] for more details.
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